Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS Statistical Report: primary brain and other Central Nervous System tumors diagnosed in the United States in 2015–2019. Neurooncology. 2022;24:v1–95. https://doi.org/10.1093/neuonc/noac202.

Article  CAS  Google Scholar 

Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN. World Health Organization 2021 Classification of Central Nervous System Tumors and implications for Therapy for adult-type gliomas: a review. JAMA Oncol. 2022;8:1493–501. https://doi.org/10.1001/jamaoncol.2022.2844.

Article  PubMed  Google Scholar 

Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004;108:49–56. https://doi.org/10.1007/s00401-004-0861-z.

Article  PubMed  Google Scholar 

Jiang T, Nam DH, Ram Z, Poon WS, Wang J, Boldbaatar D, et al. Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2021;499:60–72. https://doi.org/10.1016/j.canlet.2020.10.050.

Article  CAS  PubMed  Google Scholar 

Fan X, Wang K, Lu Q, Lu Y, Sun J. Cell-based drug Delivery systems participate in the Cancer immunity cycle for Improved Cancer Immunotherapy. Small. 2023;19:e2205166. https://doi.org/10.1002/smll.202205166.

Article  CAS  PubMed  Google Scholar 

Yasinjan F, Xing Y, Geng H, Guo R, Yang L, Liu Z, et al. Immunotherapy: a promising approach for glioma treatment. Front Immunol. 2023;14:1255611. https://doi.org/10.3389/fimmu.2023.1255611.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andersen BM, Reardon DA. Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trials. Curr Opin Neurol. 2022;35:803–13. https://doi.org/10.1097/wco.0000000000001118.

Article  CAS  PubMed  Google Scholar 

Zhao M, van Straten D, Broekman MLD, Préat V, Schiffelers RM. Nanocarrier-based drug combination therapy for glioblastoma. Theranostics. 2020;10:1355–72. https://doi.org/10.7150/thno.38147.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aghebati-Maleki A, Dolati S, Ahmadi M, Baghbanzhadeh A, Asadi M, Fotouhi A, et al. Nanoparticles and cancer therapy: perspectives for application of nanoparticles in the treatment of cancers. J Cell Physiol. 2020;235:1962–72. https://doi.org/10.1002/jcp.29126.

Article  CAS  PubMed  Google Scholar 

Yan H, Xue Z, Xie J, Dong Y, Ma Z, Sun X, et al. Toxicity of Carbon nanotubes as Anti-tumor Drug Carriers. Int J Nanomed. 2019;14:10179–94. https://doi.org/10.2147/ijn.S220087.

Article  CAS  Google Scholar 

Xu Z, Zeng S, Gong Z, Yan Y. Exosome-based immunotherapy: a promising approach for cancer treatment. Mol Cancer. 2020;19:160. https://doi.org/10.1186/s12943-020-01278-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV. Establishment and dysfunction of the blood-brain barrier. Cell. 2015;163:1064–78. https://doi.org/10.1016/j.cell.2015.10.067.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kadry H, Noorani B, Cucullo L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS. 2020;17:69. https://doi.org/10.1186/s12987-020-00230-3.

Article  PubMed  PubMed Central  Google Scholar 

Rui Y, Green JJ. Overcoming delivery barriers in immunotherapy for glioblastoma. Drug Deliv Transl Res. 2021;11:2302–16. https://doi.org/10.1007/s13346-021-01008-2.

Article  PubMed  PubMed Central  Google Scholar 

Miranda A, Blanco-Prieto M, Sousa J, Pais A, Vitorino C. Breaching barriers in glioblastoma. Part I: molecular pathways and novel treatment approaches. Int J Pharm. 2017;531:372–88. https://doi.org/10.1016/j.ijpharm.2017.07.056.

Article  CAS  PubMed  Google Scholar 

Tsvankin V, Hashizume R, Katagi H, Herndon JE, Lascola C, Venkatraman TN, et al. ABC Transporter Inhibition Plus Dexamethasone enhances the efficacy of Convection enhanced delivery in H3.3K27M mutant diffuse intrinsic pontine glioma. Neurosurgery. 2020;86:742–51. https://doi.org/10.1093/neuros/nyz212.

Article  PubMed  Google Scholar 

Wijaya J, Fukuda Y, Schuetz JD. Obstacles to Brain Tumor Therapy: Key ABC transporters. Int J Mol Sci. 2017;18. https://doi.org/10.3390/ijms18122544.

Macedo-Pereira A, Martins C, Lima J, Sarmento B. Digging the intercellular crosstalk via extracellular vesicles: may exosomes be the drug delivery solution for target glioblastoma? J Controlled Release: Official J Controlled Release Soc. 2023;358:98–115. https://doi.org/10.1016/j.jconrel.2023.04.038.

Article  CAS  Google Scholar 

Sanders S, Debinski W. Challenges to successful implementation of the Immune checkpoint inhibitors for treatment of Glioblastoma. Int J Mol Sci. 2020;21. https://doi.org/10.3390/ijms21082759.

Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20:26–41. https://doi.org/10.1038/s41568-019-0205-x.

Article  CAS  PubMed  Google Scholar 

Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neurooncology. 2018;20:184–91. https://doi.org/10.1093/neuonc/nox175.

Article  CAS  Google Scholar 

Anagnostou V, Bardelli A, Chan TA, Turajlic S. The status of tumor mutational burden and immunotherapy. Nat Cancer. 2022;3:652–6. https://doi.org/10.1038/s43018-022-00382-1.

Article  PubMed  Google Scholar 

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21. https://doi.org/10.1038/nature12477.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500–1. https://doi.org/10.1056/NEJMc1713444.

Article  PubMed  PubMed Central  Google Scholar 

Nejo T, Matsushita H, Karasaki T, Nomura M, Saito K, Tanaka S, et al. Reduced Neoantigen expression revealed by Longitudinal Multiomics as a possible Immune Evasion mechanism in Glioma. Cancer Immunol Res. 2019;7:1148–61. https://doi.org/10.1158/2326-6066.Cir-18-0599.

Article  CAS  PubMed  Google Scholar 

Dutoit V, Migliorini D, Dietrich PY, Walker PR. Immunotherapy of malignant tumors in the brain: how different from other sites? Front Oncol. 2016;6:256. https://doi.org/10.3389/fonc.2016.00256.

Article  PubMed  PubMed Central  Google Scholar 

Nejo T, Yamamichi A, Almeida ND, Goretsky YE, Okada H. Tumor antigens in glioma. Semin Immunol. 2020;47:101385. https://doi.org/10.1016/j.smim.2020.101385.

Article  CAS  Google Scholar 

Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 1990;5:953–62.

CAS  PubMed  Google Scholar 

Zagzag D, Salnikow K, Chiriboga L, Yee H, Lan L, Ali MA, et al. Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest. 2005;85:328–41. https://doi.org/10.1038/labinvest.3700233.

Article  CAS  PubMed  Google Scholar 

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565:240–5. https://doi.org/10.1038/s41586-018-0810-y.

Article